MYC and neoplasm: Mendell's lab demonstrated that systemic delivery of a miR-26a-expressing adenoviral particle via tail intravenous injections into a MYC-induced hepatocellular carcinoma mouse model resulted in inhibition of cancer cell proliferation, induction of tumor-specific apoptosis, and dramatic protection from disease progression, without toxicity (77).